Literature DB >> 8616717

Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo.

Y Manome1, P Y Wen, Y Dong, T Tanaka, B S Mitchell, D W Kufe, H A Fine.   

Abstract

Cytosine arabinoside (ara-C) is a cytidine analog that incorporates into replicating DNA and induces lethal DNA strand breaks. Although ara-C is a potent antitumor agent for hematologic malignancies, it has only minimal activity against most solid tumors. The rate-limiting step in intracellular ara-C activation is phosphorylation of the prodrug by deoxycytidine kinase (dCK). The present results demonstrate that both retroviral and adenoviral vector-mediated transduction of the dCK cDNA results in marked sensitization of glioma cells lines to the cytotoxic effects of ara-C in vitro. We also demonstrate that ara-C treatment of established intradermal and intracerebral gliomas transduced with dCK results in significant antitumor effects in vivo. These data suggest that viral vector transduction of the dCK gene followed by treatment with ara-C represents a new chemosensitization strategy for cancer gene therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8616717     DOI: 10.1038/nm0596-567

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  20 in total

Review 1.  Genetic basis of intramedullary spinal cord tumors and therapeutic implications.

Authors:  A T Parsa; A J Fiore; P C McCormick; J N Bruce
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

Review 2.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

Review 3.  Pharmacogenetics and pharmacoepigenetics of gemcitabine.

Authors:  M Candelaria; E de la Cruz-Hernández; E Pérez-Cárdenas; C Trejo-Becerril; O Gutiérrez-Hernández; A Dueñas-González
Journal:  Med Oncol       Date:  2009-11-10       Impact factor: 3.064

4.  Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.

Authors:  Soukaina Réjiba; Christelle Bigand; Céline Parmentier; Amor Hajri
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

Review 5.  Enzymes to die for: exploiting nucleotide metabolizing enzymes for cancer gene therapy.

Authors:  Andressa Ardiani; Adam J Johnson; Hongmei Ruan; Marilyn Sanchez-Bonilla; Kinta Serve; Margaret E Black
Journal:  Curr Gene Ther       Date:  2012-04-01       Impact factor: 4.391

Review 6.  Molecular chemotherapy for breast cancer.

Authors:  A Patterson; A L Harris
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

Review 7.  Gliomagenesis and the use of neural stem cells in brain tumor treatment.

Authors:  Pragathi Achanta; N I Sedora Roman; Alfredo Quiñones-Hinojosa
Journal:  Anticancer Agents Med Chem       Date:  2010-02       Impact factor: 2.505

8.  In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors.

Authors:  A Kojima; N R Hackett; A Ohwada; R G Crystal
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

Review 9.  Applications of neural and mesenchymal stem cells in the treatment of gliomas.

Authors:  Thomas Kosztowski; Hasan A Zaidi; Alfredo Quiñones-Hinojosa
Journal:  Expert Rev Anticancer Ther       Date:  2009-05       Impact factor: 4.512

Review 10.  Advances in treatment of pediatric brain tumors.

Authors:  Patricia L Robertson
Journal:  NeuroRx       Date:  2006-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.